Overview
David F. Kong, M.D., A.M., D.M.T., F.A.C.C., F.S.C.A.I. is an Associate Professor of Medicine at Duke University Medical Center and Co-Director of the Cardiovascular Late Phase 3 and Devices Unit at the Duke Clinical Research Institute. An interventional cardiologist at Duke Hospital and a faculty member in the Duke Center for Healthcare Informatics, Dr. Kong specializes in cardiovascular informatics research and integration of evidence from cardiovascular clinical trials. Dr. Kong graduated magna cum laude from HarvardUniversity, where he also received a master’s degree in Organismic and Evolutionary Biology. He received his medical degree from the Johns Hopkins University School of Medicine, and was a resident on the Osler Medical Service at the JohnsHopkinsHospital. He completed fellowships in Cardiovascular Disease and Interventional Cardiovascular Medicine at DukeUniversity before joining the Duke faculty. Dr. Kong is board certified in internal medicine, cardiology, and interventional cardiology. He is a Certified Diver Medic, Master Diver, and Dive Medical Examiner, and has been elected Fellow of the American College of Cardiology and the Society for Cardiovascular Angiography and Interventions.
Current Appointments & Affiliations
Recent Publications
Inhaled Epoprostenol Compared With Nitric Oxide for Right Ventricular Support After Major Cardiac Surgery.
Journal Article Circulation · October 24, 2023 BACKGROUND: Right ventricular failure (RVF) is a leading driver of morbidity and death after major cardiac surgery for advanced heart failure, including orthotopic heart transplantation and left ventricular assist device implantation. Inhaled pulmonary-sel ... Full text Open Access Link to item CiteThe incremental value of angiographic features for predicting recurrent cardiovascular events: Insights from the Duke Databank for Cardiovascular Disease.
Journal Article Atherosclerosis · March 2021 BACKGROUND AND AIMS: Identifying patient subgroups with cardiovascular disease (CVD) at highest risk for recurrent events remains challenging. Angiographic features may provide incremental value in risk prediction beyond clinical characteristics. METHODS: ... Full text Link to item CiteCardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure.
Journal Article N Engl J Med · January 14, 2021 BACKGROUND: The selective cardiac myosin activator omecamtiv mecarbil has been shown to improve cardiac function in patients with heart failure with a reduced ejection fraction. Its effect on cardiovascular outcomes is unknown. METHODS: We randomly assigne ... Full text Link to item CiteRecent Grants
SAFE STEMI in Seniors LOI for Volcano
Clinical TrialPrincipal Investigator · Awarded by Volcano Corporation · 2016 - 2023HARMONEE
Clinical TrialPrincipal Investigator · Awarded by Orbusneich · 2014 - 2022Advancing Medical Device Postmarket Surveillance Infrastructure and Epidemiologic Methodologies through Multi-stakeholder Partnership (U01)
ResearchCo Investigator · Awarded by Food and Drug Administration · 2013 - 2017View All Grants